LGM Pharma’s Expanded Contract Development and Manufacturing Organization (CDMO) Capabilities Will Enable Customers to Accelerate and Optimize the New Product Pathway from Early Development Through Commercialization
Boca Raton, Florida, July 27, 2020 – LGM Pharma today announced that it has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. The combination brings together LGM Pharma’s global leadership in Active Pharmaceutical Ingredient (API) sourcing, distribution and supply chain management with Nexgen Pharma’s comprehensive drug product contract development and manufacturing (CDMO) services. The combined firm, which will continue to be known as LGM Pharma, has all the capabilities needed to help pharmaceutical and biotechnology customers accelerate and optimize the new product pathway, from early R&D and clinical development through manufacturing, regulatory submission, commercialization and distribution.
LGM Pharma is a recognized global leader in sourcing and distribution of quality APIs, providing clients with streamlined API supply chain management from R&D through commercialization. LGM Pharma accesses APIs from a global network of more than 250 fully accredited CGMP manufacturing partners, optimizing API sourcing for its hundreds of customers worldwide while also providing unparalleled supply chain security and risk mitigation strategies. LGM Pharma leverages its extensive network of API suppliers to support hundreds of clients and projects in the 505(b)(2), ANDA, OTC, and compounding pharmacy markets.
Nexgen Pharma’s capabilities are highly complementary to LGM Pharma’s core business and expertise. Specializing in the development and manufacture of solid dose, powder, semi-solid, and liquid drugs, Nexgen has been manufacturing healthcare products with a rigorous commitment to quality and customer satisfaction for decades. It provides customers a comprehensive one-stop manufacturing solution that includes formulation development; analytical method development and process validation; ANDA / NDA regulatory support and submission; stability studies; raw material and finished product testing; and packaging and distribution.
The acquisition brings Nexgen’s manufacturing and warehouse distribution facilities and employees in California and Texas to LGM Pharma, along with its formulation development, laboratory, and pilot plant manufacturing employees and facilities in Colorado. In all, LGM Pharma is gaining 150 experienced employees and more than 100,000 square feet of fully equipped facilities, along with expertise in all aspects of pharmaceutical finished product development and manufacturing. The combined customer base will gain access to an expanded scope of regulatory services now available at LGM Pharma, including assisting with CMC requirements and filings and providing expert support for ANDA and NDA submissions.
“This is a transformational acquisition that allows us to greatly expand the services we provide to a substantially enlarged customer base,” said Prasad S. Raje, PhD, CEO of LGM Pharma. “As part of our continued growth and diversification strategy LGM is committed to significant investment in both infrastructure and personnel as part of this acquisition, and with the current challenges facing the industry the timing for adding U.S.-based drug product manufacturing capacity to LGM is ideal. Our complementary pharmaceutical capabilities and shared commitment to innovation, quality, and customer service will drive a vibrant and growing business that sets new standards for leadership in the pharmaceutical sector.”
“We are proud of the pharmaceutical CDMO business our family and talented employees built over many years and are delighted the business has been acquired by LGM Pharma, which is an ideal partner to carry on our tradition of quality and service while expanding the range of capabilities and services for our respective customers,” said Kyle Brown, CEO of Nexgen Pharma. “This divestiture will allow us to focus on our other healthcare segments while our pharmaceutical CDMO employees and facilities become part of a highly supportive and synergistic organization.”
Financial support for the acquisition was provided to LGM Pharma by New Harbor Capital. New Harbor Partner Jocelyn Stanley noted, “LGM Pharma has invested extensively in the organization to serve customer needs with operational excellence, resulting in significant growth over the past years. The Nexgen Pharma acquisition is highly strategic and will further accelerate this growth. We welcome the opportunity to support the company’s expansion and future success.”
BlackArch Partners served as exclusive financial advisor to Nexgen Pharma, and Stradling Yocca Carlson & Rauth served as legal advisor to Nexgen Pharma. Reed Smith served as legal advisor to LGM Pharma. Financial details of the transaction were not disclosed.
About LGM Pharma
LGM Pharma is a leading CDMO provider of comprehensive API sourcing and drug product contract development and manufacturing solutions to the pharmaceutical, biotechnology, and compounding pharmacy industries. LGM Pharma assists clients in managing all phases of the drug product development process, from Active Pharmaceutical Ingredient (API) sourcing through to commercialization. LGM Pharma’s extensive global network of qualified API partners enables clients to optimize supply chain management and distribution. Services include formulation development, analytical methods development, methods and process validation, ANDA / NDA product submission, stability studies, raw material, and finished product testing and packaging. LGM Pharma is committed to quality. It has a long-established positive regulatory track record and provides expert regulatory and market intelligence services to its clients. The company is focused on customer service and customized solutions, providing clients a comprehensive, one-stop manufacturing solution that reduces risk, increases efficiency, and accelerates the path to commercialization. For more information, visit lgmpharma.com.